These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33337818)

  • 1. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
    Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
    J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the treatment of inflammatory myopathies: a review.
    Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
    Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
    Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
    J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort.
    Gamba A; Depascale R; Zanatta E; Ienna L; Cruciani C; Gatto M; Zen M; Doria A; Iaccarino L
    Clin Rheumatol; 2024 Oct; 43(10):3167-3174. PubMed ID: 39196499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
    Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
    Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
    Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
    Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
    Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV
    Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
    Oddis CV; Reed AM; Aggarwal R; Rider LG; Ascherman DP; Levesque MC; Barohn RJ; Feldman BM; Harris-Love MO; Koontz DC; Fertig N; Kelley SS; Pryber SL; Miller FW; Rockette HE;
    Arthritis Rheum; 2013 Feb; 65(2):314-24. PubMed ID: 23124935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spectrum of idiopathic inflammatory myopathies in South Africa.
    Chinniah KJ; Mody GM
    Clin Rheumatol; 2021 Apr; 40(4):1437-1446. PubMed ID: 32212001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
    de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
    Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
    Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
    Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab as therapy for refractory polymyositis and dermatomyositis.
    Noss EH; Hausner-Sypek DL; Weinblatt ME
    J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
    Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
    Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.
    Borges IBP; Silva MG; Misse RG; Shinjo SK
    Rheumatol Int; 2018 Feb; 38(2):293-301. PubMed ID: 29027009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
    Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
    Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
    Lazarou IN; Guerne PA
    J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD.
    Mao MM; Xia S; Guo BP; Qian WP; Zheng ZX; Peng XM; Chen RC; Luo Q; Han Q
    Respir Med; 2020 Oct; 172():105983. PubMed ID: 33032789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory myopathies: evaluation and management.
    Greenberg SA
    Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.